[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100634352":3},{"organization":4,"outcomesModule":7,"designInfo":13,"detailedDescription":11,"studyPopulation":11,"armGroups":24,"interventions":37,"overallOfficials":11,"centralContacts":49,"locations":55,"responsibleParty":79,"collaborators":11,"id":81,"slug":11,"hasResults":82,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":11,"eligibilityCriteria":86,"healthyVolunteers":82,"sex":87,"minAge":88,"maxAge":89,"enrollmentInfo":90,"targetDuration":11,"studyType":93,"phases":94,"briefSummary":96,"conditions":97,"keywords":11,"overallStatus":58,"whyStopped":11,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},{"fullName":5,"class":6},"Vertex Pharmaceuticals Incorporated","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":11,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Proportion of Participants who Remain Opioid-Free",null,"From Day 1 up to Day 14",{"allocation":14,"interventionModel":15,"interventionModelDescription":11,"primaryPurpose":16,"observationalModel":11,"timePerspective":11,"maskingInfo":17},"NON_RANDOMIZED","SEQUENTIAL","TREATMENT",{"masking":18,"maskingDescription":11,"whoMasked":19},"QUADRUPLE",[20,21,22,23],"PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR",[25,31],{"label":26,"type":27,"description":28,"interventionNames":29},"Suzetrigine (SUZ)","EXPERIMENTAL","Participants will receive SUZ for 14 days.",[30],"Drug: Suzetrigine",{"label":32,"type":33,"description":34,"interventionNames":35},"Placebo","PLACEBO_COMPARATOR","Participants will receive placebo matched to SUZ for 14 days",[36],"Drug: Placebo",[38,46],{"type":39,"name":40,"description":41,"armGroupLabels":42,"otherNames":43},"DRUG","Suzetrigine","Tablets for oral administration.",[26],[44,45],"VX-548","JOURNAVX",{"type":39,"name":32,"description":47,"armGroupLabels":48,"otherNames":11},"Placebo matched to SUZ for oral administration",[32],[50],{"name":51,"role":52,"phone":53,"phoneExt":11,"email":54},"Medical Information","CONTACT","617-341-6777","medicalinfo@vrtx.com",[56,70],{"facility":57,"status":58,"city":59,"state":60,"zip":61,"country":62,"countryCode":63,"cosmosGeoPoint":64,"geoPoint":69,"contacts":11},"Legent Orthopedic and Spine Hospital","RECRUITING","Bellaire","Texas","77401","United States","US",{"type":65,"coordinates":66},"Point",[67,68],-95.45883,29.70579,{"lat":68,"lon":67},{"facility":71,"status":58,"city":72,"state":60,"zip":73,"country":62,"countryCode":63,"cosmosGeoPoint":74,"geoPoint":78,"contacts":11},"Memorial Hermann Village Office","Houston","77043",{"type":65,"coordinates":75},[76,77],-95.36327,29.76328,{"lat":77,"lon":76},{"type":80,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100634352",false,"NCT07538570","Evaluation of Pain Treatment After Total Knee Arthroplasty","A Phase 4, Double-blind, Sequential Cohort Study of Pain Treatment and Recovery After Total Knee Arthroplasty","Key Inclusion Criteria:\n\n* Body mass index (BMI) of greater than or equal to (≥) 18.0 to less than or equal to (≤) 40.0 kilogram per meter square (kg\u002Fm\\^2)\n* Scheduled to undergo an elective primary unilateral TKA surgery\n\nKey Exclusion Criteria:\n\n\\- History of previous TKA surgery on incident side\n\nOther protocol defined Inclusion\u002FExclusion criteria will apply.","ALL","18 Years","80 Years",{"count":91,"type":92},60,"ESTIMATED","INTERVENTIONAL",[95],"PHASE4","The purpose of the study is to characterize opioid use after total knee arthroplasty (TKA).",[98],"Pain","2026-05-08",{"date":101,"type":102},"2026-05-13","ACTUAL",{"date":104,"type":102},"2026-04-24",{"date":106,"type":92},"2027-01-30",{"name":5,"class":6},2]